Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | METAP1 | P53582 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | CA1 | P00915 | 2/20 | 0.38 |
| ▸ | CA12 | O43570 | 1/20 | 0.38 |
| ▸ | CA9 | Q16790 | 1/20 | 0.38 |
| ▸ | PSMB8 | P28062 | 1/20 | 0.38 |
| ▸ | CYP17A1 | P05093 | 2/20 | 0.37 |
| ▸ | ATR | Q13535 | 1/20 | 0.37 |
| ▸ | CA2 | P00918 | 1/20 | 0.36 |
| ▸ | LCK | P06239 | 1/20 | 0.36 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.36 |
| ▸ | NAMPT | P43490 | 1/20 | 0.35 |
| ▸ | MIF | P14174 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2928945 | 0.81 | CA12 (0.45) | METAP1MEN1KMT2ASMN1; SMN2CA1 | |
| SCHEMBL9291119 | 0.81 | METAP1 (0.50) | METAP1MEN1KMT2ASMN1; SMN2CA1 | |
| SCHEMBL399916 | 0.80 | METAP1 (0.43) | METAP1MEN1KMT2ASMN1; SMN2CA1 | |
| SCHEMBL1703501 | 0.79 | PTPN2 (0.58) | METAP1MEN1KMT2ASMN1; SMN2PTK2 | |
| SCHEMBL395773 | 0.79 | METAP1 (0.48) | METAP1SMN1; SMN2CA1CA12CA9 | |
| SCHEMBL29951266 | 0.79 | METAP1 (0.42) | METAP1MEN1KMT2ASMN1; SMN2CA1 | |
| SCHEMBL6969183 | 0.78 | ALDH1A1 (0.44) | METAP1MEN1KMT2ASMN1; SMN2CA1 | |
| SCHEMBL1703720 | 0.78 | KMT2A (0.66) | MEN1KMT2ASMN1; SMN2ATR | |
| SCHEMBL14291444 | 0.77 | ALDH1A1 (0.42) | METAP1MEN1KMT2ASMN1; SMN2CA1 | |
| SCHEMBL13116571 | 0.76 | METAP1 (0.41) | METAP1MEN1KMT2ASMN1; SMN2CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115611895-A | Arylamino derivative estrogen receptor modulators and uses thereof | 四川海思科制药有限公司 | 2023-01-17 | — | — | CN | disclosed |
| US-8101645-B2 | Thienopyrroles and pyrrolothiazoles as new therapeutic agents | ABBOTT LABORATORIES (US) | 2012-01-24 | — | — | US | disclosed |
| WO-2011079105-A1 | NOVEL THIENOPYRROLE COMPOUNDS | ABBOTT LABORATORIES (US) | 2011-06-30 | — | — | WO | disclosed |
| US-20110152243-A1 | NOVEL THIENOPYRROLE COMPOUNDS | ABBOTT LABORATORIES (US) | 2011-06-23 | — | — | US | disclosed |
| EP-2268281-A1 | THIENOPYRROLES AND PYRROLOTHIAZOLES AS NEW THERAPEUTIC AGENTS | Abbott Laboratories (US) | 2011-01-05 | — | — | EP | disclosed |
| WO-2009102462-A1 | THIENOPYRROLES AND PYRROLOTHIAZOLES AS NEW THERAPEUTIC AGENTS | ABBOTT LABORATORIES (US) | 2009-08-20 | — | — | WO | disclosed |
| US-20090209609-A1 | Thienopyrroles and pyrrolothiazoles as new therapeutic agents | ABBVIE INC. | 2009-08-20 | — | — | US | disclosed |
| CN-100443487-C | N-sulfonylheterocyclopyrrolylalkylamine compounds as 5-hydroxytryptamine-6 ligands | WYETH CORP (US) | 2008-12-17 | — | — | CN | disclosed |
| EP-1648904-B1 | N-SULFONYLHETEROCYCLOPYRROLYLALKYLAMINE COMPOUNDS AS 5-HYDROXYTRYPTAMINE-6 LIGANDS | WYETH CORP (US) | 2007-08-22 | — | — | EP | disclosed |
| US-7220756-B2 | N-sulfonylheterocyclopyrrolyl-alkylamine compounds as 5-hydroxytryptamine-6 ligands | WYETH (US) | 2007-05-22 | — | — | US | disclosed |
| US-7220756-B2 | N-sulfonylheterocyclopyrrolyl-alkylamine compounds as 5-hydroxytryptamine-6 ligands | WYETH (US) | 2007-05-22 | — | — | US | disclosed |
| US-7220756-B2 | N-sulfonylheterocyclopyrrolyl-alkylamine compounds as 5-hydroxytryptamine-6 ligands | WYETH (US) | 2007-05-22 | — | — | US | disclosed |
| CN-1826346-A | N-sulfonylheterocyclopyrrolylalkylamine compounds as 5-hydroxytryptamine-6 ligands | WYETH CORP (US) | 2006-08-30 | — | — | CN | disclosed |
| US-20060160878-A1 | N-sulfonylheterocyclopyrrolyl-alkylamine compounds as 5-hydroxytryptamine-6 ligands | WYETH (US) | 2006-07-20 | — | — | US | disclosed |
| US-7041695-B2 | N-sulfonylheterocyclopyrrolyl-alkylamine compounds as 5-hydroxytryptamine-6 ligands | WYETH (US) | 2006-05-09 | — | — | US | disclosed |
| EP-1648904-A1 | N-SULFONYLHETEROCYCLOPYRROLYLALKYLAMINE COMPOUNDS AS 5-HYDROXYTRYPTAMINE-6 LIGANDS | Wyeth (US) | 2006-04-26 | — | — | EP | disclosed |
| US-20050038088-A1 | N-sulfonylheterocyclopyrrolyl-alkylamine compounds as 5-hydroxytryptamine-6 ligands | WYETH (US) | 2005-02-17 | — | — | US | disclosed |
| WO-2005012311-A1 | N-SULFONYLHETEROCYCLOPYRROLYLALKYLAMINE COMPOUNDS AS 5-HYDROXYTRYPTAMINE-6 LIGANDS | WYETH (US) | 2005-02-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050038088-A1 | N-sulfonylheterocyclopyrrolyl-alkylamine compounds as 5-hydroxytryptamine-6 ligands | HTR6, HTR5A, HTR1A | METAP1 898/4885MEN1 1479/4885KMT2A 2852/4885 |
| US-20110152243-A1 | NOVEL THIENOPYRROLE COMPOUNDS | TPMT, TSLP, THPO | METAP1 933/4885MEN1 427/4885KMT2A 3648/4885 |
| US-20090209609-A1 | Thienopyrroles and pyrrolothiazoles as new therapeutic agents | HRH2, HRH1, TSLP | METAP1 873/4885MEN1 4412/4885KMT2A 3711/4885 |
| US-20060160878-A1 | N-sulfonylheterocyclopyrrolyl-alkylamine compounds as 5-hydroxytryptamine-6 ligands | HTR6, HTR5A, HTR1A | METAP1 898/4885MEN1 1479/4885KMT2A 2852/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.